8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Predicting pharmacy syringe sales to people who inject drugs: Policy, practice and perceptions

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Pharmacies have much to contribute to the health of people who inject drugs (PWID) and to community efforts in HIV and hepatitis C (HCV) prevention through syringe access. However, little is known about what predicts pharmacy syringe sales without a prescription.

          Objective:

          To identify factors predicting pharmacy syringes sales to PWID.

          Methods:

          A hybrid staggered online survey of 298 Indiana community pharmacists occurred from July-September 2016 measuring pharmacy policy, practice, and pharmacist perceptions about syringe sales to PWID. Separate bivariate logistical regressions were followed by multivariable logistic regression to predict pharmacy syringe sales and pharmacist comfort dispensing syringes to PWID.

          Results:

          Half (50.5%) of Indiana pharmacies sold syringes without a prescription to PWID. Pharmacy syringe sales was strongly associated with pharmacist supportive beliefs about syringe access by PWID and their comfort level selling syringes to PWID. Notably, pharmacies located in communities with high rates of opioid overdose mortality were 56% less likely to sell syringes without a prescription than those in communities with lower rates. Pharmacist comfort dispensing syringes was associated with being male, working at a pharmacy that sold syringes to PWID and one that stocked naloxone, having been asked about syringe access by medical providers, and agreement that PWID should be able to buy syringes without a prescription.

          Conclusions:

          As communities with high rates of opioid overdose mortality were less likely to have pharmacies that dispensed syringes to PWID, a concerted effort with these communities and their pharmacies should be made to understand opportunities to increase syringe access. Future studies should explore nuances between theoretical support for syringe access by PWID without a prescription and actual dispensing behaviors. Addressing potential policy conflicts and offering continuing education on non-prescription syringe distribution for pharmacists may improve comfort distributing syringes to PWID, and therefore increase pharmacy syringe sales.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: not found
          • Article: not found

          Increases in Drug and Opioid Overdose Deaths-United States, 2000-2014

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone — Indiana, 2015

            On January 23, 2015, the Indiana State Department of Health (ISDH) began an ongoing investigation of an outbreak of human immunodeficiency virus (HIV) infection, after Indiana disease intervention specialists reported 11 confirmed HIV cases traced to a rural county in southeastern Indiana. Historically, fewer than five cases of HIV infection have been reported annually in this county. The majority of cases were in residents of the same community and were linked to syringe-sharing partners injecting the prescription opioid oxymorphone (a powerful oral semi-synthetic opioid analgesic). As of April 21, ISDH had diagnosed HIV infection in 135 persons (129 with confirmed HIV infection and six with preliminarily positive results from rapid HIV testing that were pending confirmatory testing) in a community of 4,200 persons (1). The age range of the 135 patients is 18–57 years (mean = 35 years; median = 32 years); 74 (54.8%) are male. A small number of pregnant women were diagnosed with HIV infection and started on antiretroviral therapy during pregnancy. As of April 21, no infants had tested positive for HIV. Of the 135 persons with diagnosed HIV infection, 108 (80.0%) have reported injection drug use (IDU), four (3.0%) have reported no IDU, and 23 (17.0%) have not been interviewed to determine IDU status. Among the 108 who have reported IDU, all reported dissolving and injecting tablets of oxymorphone as their drug of choice. Some reported injecting other drugs, including methamphetamine and heroin. Ten (7.4%) female patients have been identified as commercial sex workers. Coinfection with hepatitis C virus has been diagnosed in 114 (84.4%) patients. The patients were interviewed about syringe-sharing and sex partners, as well as any social contacts who also might have engaged in high risk behaviors. Those interviewed reported an average of nine syringe-sharing partners, sex partners, or other social contacts who might be at risk for HIV infection. Of the 373 contacts named as of April 21, a total of 247 (66.2%) had been located, 230 (61.7%) were tested, and 17 (4.6%) either declined testing or were not able to be tested. Of the 230 contacts who were tested, test results for 109 (47.4%) were HIV positive, and 121 (52.6%) were HIV negative. Of the 128 contacts who have not yet been located, 74 (57.8%) have been identified as syringe-sharing or sex partners, and 54 (42.2%) are social contacts regarded as at high risk for HIV infection. Injection drug use in this community is a multi-generational activity, with as many as three generations of a family and multiple community members injecting together. IDU practices include crushing and cooking extended-release oxymorphone, most frequently 40 mg tablets not designed to resist crushing or dissolving. Syringes and drug preparation equipment are frequently shared (e.g., the drug is dissolved in nonsterile water and drawn up into an insulin syringe that is usually shared with others). The reported daily numbers of injections ranged from four to 15, with the reported number of injection partners ranging from one to six per injection event. Like many other rural counties in the United States, the county has substantial unemployment (8.9%), a high proportion of adults who have not completed high school (21.3%), a substantial proportion of the population living in poverty (19%), and limited access to health care (1). This county consistently ranks among the lowest in the state for health indicators and life expectancy (2). ISDH worked with the only health care provider in the immediate community, local health officials, law enforcement, community partners, regional health care providers and CDC to launch a comprehensive response to this outbreak. A public health emergency was declared on March 26 by executive order (3). The response has included a public education campaign, establishment of an incident command center and a community outreach center, short-term authorization of syringe exchange, and support for comprehensive medical care including HIV and hepatitis C virus care and treatment as well as substance abuse counseling and treatment. State and local health departments and academic partners, with the assistance of CDC, are working to implement and improve the community outreach programs supported by the executive order and to interrupt IDU-related HIV and hepatitis C virus transmission. Contact tracing by state and CDC disease intervention specialists continues to identify those potentially exposed. This HIV outbreak involves a rural population, historically at low risk for HIV, in which HIV infection spread rapidly within a large network of persons who injected prescription opioids. The Indiana public health response includes implementing programs to contain the spread of HIV and hepatitis C virus, curb injection drug use, and concurrently build social resilience in the community. The outbreak highlights the vulnerability of many rural, resource-poor populations to drug use, misuse, and addiction, in the context of a high prevalence of unaddressed comorbid conditions (4). The outbreak also demonstrates the importance of timely HIV and Hepatitis C surveillance activities and rapid response to interrupt disease transmission. Finally, the outbreak points to the need for expanded mental health and substance use treatment programs in medically underserved rural areas (5).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes.

              We assessed the effects of syringe exchange program (SEP) policy on rates of HIV risk behavior and HIV incidence among injection drug users. Using a multivariate generalized estimating equation and Cox regression methods, we examined syringe borrowing, syringe lending, and HIV incidence among a prospective cohort of 1228 injection drug users in Vancouver, British Columbia. We observed substantial declines in rates of syringe borrowing (from 20.1% in 1998 to 9.2% in 2003) and syringe lending (from 19.1% in 1998 to 6.8% in 2003) following SEP policy change. These declines coincided with a statistically significant increase in the proportion of participants accessing sterile syringes from nontraditional SEP sources (P < .001). In multivariate analyses, the period following the change in SEP policy was independently associated with a greater than 40% reduction in syringe borrowing (adjusted odds ratio [AOR] = 0.57; 95% confidence interval [CI] = 0.49, 0.65) and lending (AOR = 0.52; 95% CI = 0.45, 0.60), as well as declining HIV incidence (adjusted hazard ratio = 0.13; 95% CI = 0.06, 0.31). Widespread syringe distribution appears to be a more effective SEP policy than do more restrictive SEP policies that limit syringe access. Efforts should be made to ensure that SEP policies and program design serve to maximize rather than hinder syringe access.
                Bookmark

                Author and article information

                Journal
                9014759
                21498
                Int J Drug Policy
                Int. J. Drug Policy
                The International journal on drug policy
                0955-3959
                1873-4758
                10 February 2019
                17 March 2018
                June 2018
                01 June 2019
                : 56
                : 46-53
                Affiliations
                [a ]Indiana University School of Public Health-Bloomington, 1025 E. 7th Street, Bloomington, IN 47405 USA
                [b ]Rural Center for AIDS/STD Prevention, Indiana University, 1025 E. 7th Street, Bloomington, IN 47405 USA
                [c ]HIV Center for Clinical and Behavioral Studies, Columbia University Medical Center and New York Psychiatric Institute, 1051 Riverside Dr # 15, New York, NY 10032, USA
                [d ]Social Intervention Group, Columbia University School of Social Work, 1255 Amsterdam Ave, New York, NY 10027, USA
                [e ]Indiana Prevention Research Center, Indiana University, 501 N Morton St # 110, Bloomington, IN 47404, USA
                [f ]Larkin University College of Pharmacy, 18301 N Miami Ave Suite 1, Miami, FL 33169, USA
                [g ]Butler University College of Pharmacy and Health Sciences, 4600 Sunset Ave, Indianapolis, IN 46208, USA
                [h ]Institute for Research on Addictive Behavior, Indiana University, 501 N Morton St # 110, Bloomington, IN 47404, USA
                Author notes

                Contributors

                All authors have nothing to disclose.

                [* ]Corresponding author at: Indiana University School of Public Health-Bloomington, Indiana USA, 1025 E. 7th Street, Bloomington, IN 47405, USA., bmeyerso@ 123456indiana.edu (B.E. Meyerson).
                Article
                NIHMS1011031
                10.1016/j.drugpo.2018.02.024
                6375077
                29558701
                ceacbc96-b7f0-442e-a14f-267acd70185a

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/BY-NC-ND/4.0/).

                History
                Categories
                Article

                Social policy & Welfare
                syringe access,hepatitis c prevention,pharmacy public health,hiv prevention

                Comments

                Comment on this article